Technology  September 1, 2022

Flagship Biosciences acquires business unit from Interpace Biosciences

BROOMFIELD — Flagship Biosciences Inc., a biotechnology company that uses artificial intelligence to analyze tissue samples, has acquired Interpace Pharma Solutions, a division of New Jersey-based Interpace Biosciences that specializes in cytogenetic, molecular pathology, and genomic profiling solutions.

Terms of the deal were not disclosed, but Flagship said the acquisition accrued after the close of an unspecified equity investment from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corp. Technologies.

The acquisition allows Flagship to plant its flag in the North Carolina Research Triangle, which, like the Boulder Valley, is a hotbed for life-sciences companies. 

“By combining these organizations, we create a single-source…

Related Posts

Sign up for BizWest Daily Alerts
Closing in 8 seconds...